According to domestic media reports on August 12, Satidhar Jain, director of the Health Bureau of the New Delhi District of India's national capital, said a few days ago that New Delhi has "defeated" the new crown Delta mutation. However, bad news in India is frequent, and the Indian people are crying bitterly.
According to the Times of India, Jia Yin recently claimed that during the second wave of the local epidemic and after that, the Delta strain accounted for more than 80% of the new coronavirus samples sent for genome sequencing, but New Delhi has "defeated" the new crown Delta strain. He also stressed, "Given that the Delta variant originated in India, we already felt its severity during the second wave of the outbreak. Other countries must be prepared because the outbreak is spreading there. New Delhi has dealt with the Delta mutant and defeated the outbreak. ”
It is worth noting that despite Jia Yin's claim that the local people have defeated the new crown epidemic, the local people still have not lived a good life, but have fallen into another nightmare. According to media reports, a deadly fungus, Mucormyces (or "melanobacteria"), is sweeping across India, where more than 45,000 cases of mucormycosis have been reported so far, 85 percent of which have had COVID-19. However, indians suffering from mucormycosis will "mold" and die within a few days if they are not treated in time. One study showed that its mortality rate was more than 50 percent.
It should be mentioned that since May, more than a dozen States in India have declared that Mucormyces has become a new epidemic. In late May, Indian Prime Minister Narendra Modi also made it clear that the spread of mucormycosis has become a new challenge facing India in the fight against the epidemic. In addition to mucormycosis, India has also appeared white, yellow and green fungal diseases. An Indian scientist wrote in the Hindustan newspaper that mucormyces is only the tip of the iceberg.
However, there is currently a shortage of drugs to treat mucormycosis in India. According to the Indian Express, many Indians cannot buy amphotericin B as a "life-saving drug" for the treatment of mucormycosis, whether they are running around or ruining their homes; what is more difficult is that although many local governments in India have announced that public hospitals exempt mucormycosis patients from certain fees, due to limited medical resources, poor People in India can only be forced into expensive private hospitals. According to the Indian Express, due to the inability to afford the high cost of treatment, many patients with mucormycosis in India chose to leave the hospital halfway and actively chose to stop treatment.
In the eventful autumn, the surging news reported on August 11 that signs of a third wave of the new crown epidemic in India have been seen in at least 10 states, and the southern states of Tamil Nadu, Karnataka, Kerala and other states have reported an increase in the R0 value (the number of people infected per infected person), which means that everyone infected with the virus will transmit the virus to more people than in the past three months. It should be mentioned that on August 2, two teams of the Indian Institute of Technology released a research report showing that the third wave of the new crown pneumonia epidemic in India is likely to hit in October, when the number of confirmed cases of new crown pneumonia in the country in a single day may reach 100,000 to 150,000.